Ph.D. , both economists at the University of York in the UK. The technique puts a value on reducing uncertainty. It does this by calculating how the costs and consequences of decisions made with current evidence differ from those made with future evidence that resolves key unknowns. Should the future evidence prove more valuable than the current evidence, then undertaking research to obtain it makes sense, especially if the associated costs can be justifi ed.
This approach is, of course, challenging, because it's impossible to know in advance how a particular study will turn out. But that doesn't mean that researchers can't make educated guesses about what the data could look like. They can infer outcomes on the basis of preliminary studies in animals or people, for instance, or on more indirect information, such as knowledge of the drug's mechanism of action.
A VOI analysis explicitly describes these predictions, along with downstream consequences for affected patient populations. "VOI leads you to ask, 'How uncertain are we about a given issue in health care? ' 'How much do we lose as a consequence of that uncertainty? ' and 'How much do we gain by resolving it? ' " Claxton explained.
To illustrate how SWOG might use VOI in its funding decisions, Fred Hutchinson's Ramsey offered this example: Consider a drug that looks promising in phase II for pancreas cancer -which is rare, deadly, and resistant to therapy -versus a phase II trial for a drug in breast cancer with positive lymph nodes, which is common, not so deadly, and for which many, albeit imperfect, treatments are available. The VOI approach, he explained, would model trial costs, number of future patients likely to be affected by either disease, potential clinical benefi ts from treatment, and drug costs to payers, with each parameter contributing to an overall estimate of the treatment's clinical value. If the quality of the science behind those parameters was similar, he said, SWOG might want to go with the trial that offers information with the most value, i.e., the best VOI.
VOI ordinarily presents options in fi nancial terms so that researchers can compare how medical value, measured in quality-adjusted life-years (QALYs), for instance, varies among competing clinical trials. QALYs assign monetary value to 1 year of life saved by treatment, adjusted for the loss in quality from drug side effects and other symptoms of being sick. Countries with national health care use QALYs to compare expected societal benefi ts from one treatment versus another. The UK's Health Technology Assessment Program, for example, which selects clinical trials for funding, bases those decisions in part on a QALY-based VOI system. But in the United States, where the medical economy is more diffuse, and where cost controls in health care are politically vulnerable, a monetized VOI system could be problematic. Neither Baker nor anyone else with a role in health care delivery wants to be seen as denying opportunities for medical improvement on the basis of cost.
"For us, monetizing VOI is the wrong approach," he said fl atly. "Sure, if two trials offer the same clinical benefi ts for different prices, then obviously you choose the one that's less expensive. But things are rarely so simple." And ideally, Baker added, clinical benefi ts expressed by VOI will not be limited to overall survival. "We would propose to choose the endpoint that would demonstrate the most clinical benefi t," he said. "If the endpoint is progression-free survival versus overall survival, then that's fi ne. If the endpoint is volume decrease in tumor burden associated with increase in performance-this would need to be developed-then so be it." McClellan said in an e-mail that "some exciting work is under way to streamline the methods of VOI analysis so it can be used to assess a large number of potential research investments in a timely way."
Peter Neumann, Sc.D. , a professor at Tufts University School of Medicine in Boston, warns that VOI-enabled decision making could face a backlash from those who object to making funding choices so dispassionately. "Funding committees could face a perception that they're hiding behind a veil of science and calculation," he said. "And people who don't like their conclusions might push back on those grounds."
Defining Benefits
Another challenge, Neumann said, is that VOI originated from cost -benefi t analysis, and most applications to date have used QALYs to compare how research alternatives match up around a shared financial metric. "They serve a very useful function in that regard, and it could be diffi cult to compare diverse treatments with a non -QALY-based system," he said. "You need some sort of common currency, and that's what QALYs offer -they can be applied to any disease, treatment, or intervention. So, it's not clear what other metric you might use, although if you're just comparing endpoints in oncology, this might not be so problematic."
Still, although experts here tread carefully on the cost issue, drug prices are a constant concern. "We need to fi gure out costs in relation to effectiveness, and VOI will force that issue," Ramsey said. "But this isn't so much about cost control as it is about prioritizing research on both clinical and economic grounds," he said. He pointed to trials now looking at long-term uses of drugs that cost thousands of dollars per month and may have little benefi t. "If the expected benefi t is just a few weeks of life, then that's a terrible value proposition, and not one I would want to fund."
Finally, some experts worry that VOIbased prioritization could undermine investments into rare diseases. VOI expresses benefi ts in population terms; that means that investments into highly prevalent diseases such as lung, breast, and colon cancer could been seen as more clinically valuable than investments into less common illnesses. McClellan cautioned that VOI could be helpful in setting research priorities only if it were used in conjunction with "other important considerations, such as the needs of vulnerable populations and patients with rare illnesses." Sculpher acknowledged that "by defi nition" VOI would ascribe less value to trials that benefi t fewer patients. But he added that it's not necessarily true that trials for rare diseases would lose out. That's both because smaller trials cost less than large trials geared toward more common illnesses and because rare diseases typically have more associated uncertainties, he said. And under a VOI framework, the value of resolving uncertainty increases with the magnitude of the uncertainty.
But he added that decision makers here still need to determine how to defi ne 
